Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

January 28, 2025

Study Completion Date

January 28, 2025

Conditions
Interstitial Cystitis/Bladder Pain Syndrome
Interventions
DRUG

V117957

V117957 1 mg - 1 tablet taken orally at bedtime.

DRUG

Placebo

Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.

Trial Locations (24)

10016

Manhattan Medical Research Practice, New York

11530

AccuMed Research Associates, Garden City

19004

MidLantic Urology, Bala-Cynwyd

21117

Chesapeake Urology Research Associates, Owings Mills

27103

Unified Women's Clinical Research-Lyndhurst Clinical Research, Winston-Salem

30033

Accel Research Site - Neurostudies, Decatur

32720

Accel Research Sites, DeLand

35209

Urology Centers of Alabama, PC, Homewood

41017

Otrimed Clinical Research, Edgewood

44109

MetroHealth System, Cleveland

48127

Revive Research Institute, Inc, Dearborn Heights

56377

CentraCare - Urology Clinic, Sartell

60805

Providea Health Partners LLC, Evergreen Park

68114

Adult & Pediatric Urology P.C., Omaha

70001

Southern Clinical Research Associates, Metairie

71106

Ochsner Louisiana State University Health Shreveport - Regional University, Shreveport

72212

Applied Research Center of Arkansas, Little Rock

85715

Urological Associates of Southern Arizona, Tucson

90017

Urology Group of Southern California, Los Angeles

91303

Hope Clinical Research, LLC, Los Angeles

92025

Investigational Site, Escondido

92562

Tri Valley Urology Medical Group, Murrieta

02131

Boston Clinical Trials, Boston

02472

Bay State Clinical Trials, Inc., Watertown

Sponsors
All Listed Sponsors
collaborator

Purdue Pharma LP

INDUSTRY

lead

Imbrium Therapeutics

INDUSTRY

NCT06285214 - Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome | Biotech Hunter | Biotech Hunter